Multiple studies demonstrate Guardant Infinity’s
high specificity and sensitivity for methylation-based
MRD detection without requiring up-front tissue1-3
Trial
COSMOS
TRACER
QUANTIFY CANCER
New studies support
methylation-based ctDNA detection with Guardant Infinity after curative
intent therapy.1-3
SUCCESS-A
ctDNA, circulating tumor DNA; MRD, minimal residual disease.
Indication
Stage II/III
colon cancer
Early-stage
breast cancer
Early-stage
breast cancer
Home Guardant Infinity™ for BioPharma Guardant360® CDx for BioPharma